JP2020537520A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020537520A5 JP2020537520A5 JP2020520050A JP2020520050A JP2020537520A5 JP 2020537520 A5 JP2020537520 A5 JP 2020537520A5 JP 2020520050 A JP2020520050 A JP 2020520050A JP 2020520050 A JP2020520050 A JP 2020520050A JP 2020537520 A5 JP2020537520 A5 JP 2020537520A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence
- antibody
- amino acid
- scfv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 6
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 5
- 239000011780 sodium chloride Substances 0.000 claims 3
- 238000002965 ELISA Methods 0.000 claims 2
- 241000282567 Macaca fascicularis Species 0.000 claims 2
- 229910019142 PO4 Inorganic materials 0.000 claims 2
- 239000007979 citrate buffer Substances 0.000 claims 2
- 102000050327 human TNFRSF9 Human genes 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 2
- 239000010452 phosphate Substances 0.000 claims 2
- 238000003860 storage Methods 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 101100099884 Homo sapiens CD40 gene Proteins 0.000 claims 1
- 101000638251 Homo sapiens Tumor necrosis factor ligand superfamily member 9 Proteins 0.000 claims 1
- 101000679851 Homo sapiens Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 238000010494 dissociation reaction Methods 0.000 claims 1
- 230000005593 dissociations Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 102000050320 human TNFRSF4 Human genes 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- 238000002844 melting Methods 0.000 claims 1
- 230000008018 melting Effects 0.000 claims 1
- 239000000178 monomer Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000007981 phosphate-citrate buffer Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17195780.6A EP3470428A1 (en) | 2017-10-10 | 2017-10-10 | Antibodies targeting cd137 and methods of use thereof |
| EP17195780.6 | 2017-10-10 | ||
| EP18167092 | 2018-04-12 | ||
| EP18167092.8 | 2018-04-12 | ||
| EP18180815 | 2018-06-29 | ||
| EP18180815.5 | 2018-06-29 | ||
| PCT/EP2018/077514 WO2019072870A1 (en) | 2017-10-10 | 2018-10-09 | ANTIBODIES TARGETING CD137 AND METHODS OF USE |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020537520A JP2020537520A (ja) | 2020-12-24 |
| JP2020537520A5 true JP2020537520A5 (OSRAM) | 2021-11-18 |
| JP7438939B2 JP7438939B2 (ja) | 2024-02-27 |
Family
ID=63834023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020520050A Active JP7438939B2 (ja) | 2017-10-10 | 2018-10-09 | Ｃｄ１３７を標的とする抗体とその利用方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11578133B2 (OSRAM) |
| EP (1) | EP3694880A1 (OSRAM) |
| JP (1) | JP7438939B2 (OSRAM) |
| KR (1) | KR20200063153A (OSRAM) |
| CN (1) | CN111183159B (OSRAM) |
| AU (1) | AU2018348431B2 (OSRAM) |
| CA (1) | CA3075337A1 (OSRAM) |
| IL (1) | IL273841B1 (OSRAM) |
| MA (1) | MA50354A (OSRAM) |
| SG (1) | SG11202003111SA (OSRAM) |
| WO (1) | WO2019072870A1 (OSRAM) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3585431A4 (en) | 2017-02-24 | 2020-12-16 | MacroGenics, Inc. | BISPECIFIC BINDING MOLECULES CAPABLE OF BINDING TO CD137 AND TUMOR ANTIGENS, AND THEIR USES |
| ES3015094T3 (en) * | 2017-06-05 | 2025-04-29 | Numab Therapeutics AG | Anti-hsa antibodies |
| AU2018348429B2 (en) * | 2017-10-10 | 2025-08-28 | Numab Therapeutics AG | Multispecific antibody |
| EP3835321A4 (en) | 2018-08-10 | 2022-11-02 | Chugai Seiyaku Kabushiki Kaisha | ANTI-CD137 ANTIGEN-BINDING MOLECULE AND USE THEREOF |
| CA3144617A1 (en) * | 2019-06-26 | 2020-12-30 | Ap Biosciences, Inc. | Antibodies for t-cell activation |
| WO2021013142A1 (zh) * | 2019-07-22 | 2021-01-28 | 江苏恒瑞医药股份有限公司 | 抗4-1bb抗体、其抗原结合片段及双特异性抗体 |
| CN117843786A (zh) * | 2019-11-19 | 2024-04-09 | 非同（成都）生物科技有限公司 | 人源化4-1bb单克隆抗体及其药物组合物 |
| TWI895351B (zh) * | 2020-02-12 | 2025-09-01 | 日商中外製藥股份有限公司 | 用於癌症之治療的抗cd137抗原結合分子 |
| WO2021170067A1 (zh) * | 2020-02-28 | 2021-09-02 | 上海复宏汉霖生物技术股份有限公司 | 抗cd137构建体及其用途 |
| WO2021236658A1 (en) | 2020-05-19 | 2021-11-25 | Boehringer Ingelheim International Gmbh | Binding molecules for the treatment of cancer |
| JP2024509915A (ja) * | 2021-03-09 | 2024-03-05 | ジェンマブ エー／エス | 治療におけるｃｄ４０およびｃｄ１３７に対する多重特異性結合物質 |
| EP4395824A4 (en) * | 2021-09-03 | 2025-10-22 | Novarock Biotherapeutics Ltd | BISPECIFIC AND TRISPECIFIC PD-L1, CD137 AND/OR TGF-BETA BINDING PROTEINS AND USES THEREOF |
| KR102647506B1 (ko) | 2022-02-22 | 2024-03-13 | 방윤배 | 실내 벽체 고정용 골조보강패널 |
| WO2024240690A2 (en) * | 2023-05-19 | 2024-11-28 | Numab Therapeutics AG | Antibody variable domains and antibodies having decreased immunogenicity |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US5013653A (en) | 1987-03-20 | 1991-05-07 | Creative Biomolecules, Inc. | Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| DE3853515T3 (de) | 1987-05-21 | 2005-08-25 | Micromet Ag | Multifunktionelle proteine mit vorbestimmter zielsetzung. |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| DE69233204T2 (de) | 1991-12-13 | 2004-07-15 | Xoma Corp., Berkeley | Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| EP0985039B1 (en) | 1997-06-12 | 2008-02-20 | Novartis International Pharmaceutical Ltd. | Artificial antibody polypeptides |
| DE19819846B4 (de) | 1998-05-05 | 2016-11-24 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Multivalente Antikörper-Konstrukte |
| KR20000034847A (ko) * | 1998-11-17 | 2000-06-26 | 성재갑 | 인간 4-1비비 분자에 대한 인간화 항체 및 이를 포함하는 약학조성물 |
| US6887673B2 (en) | 2002-07-30 | 2005-05-03 | Bristol-Myers Squibb Company | Humanized antibodies against human 4-1BB |
| KR101411165B1 (ko) | 2005-07-01 | 2014-06-25 | 메다렉스, 엘.엘.시. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체 |
| JP5602625B2 (ja) | 2007-06-26 | 2014-10-08 | エフ−スター ビオテヒノロギッシェ フォルシュングス− ウント エントヴィッケルングスゲゼルシャフト ミット ベシュレンクテル ハフツング | 結合物質のディスプレイ |
| WO2010077634A1 (en) | 2008-12-09 | 2010-07-08 | Genentech, Inc. | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| NZ599405A (en) | 2009-11-24 | 2014-09-26 | Medimmune Ltd | Targeted binding agents against b7-h1 |
| MX337040B (es) | 2010-09-09 | 2016-02-09 | Pfizer | Moleculas de union a 4-1bb. |
| EP2785375B1 (en) | 2011-11-28 | 2020-07-22 | Merck Patent GmbH | Anti-pd-l1 antibodies and uses thereof |
| CN105940014A (zh) * | 2013-10-25 | 2016-09-14 | 努马布有限公司 | 双特异性构造及其在治疗各种疾病中的用途 |
| MA41044A (fr) * | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
| EA201890041A1 (ru) | 2015-06-15 | 2018-07-31 | Нумаб Инновейшн Аг | Гетеродимерный полиспецифичный формат антител |
| AU2018348429B2 (en) * | 2017-10-10 | 2025-08-28 | Numab Therapeutics AG | Multispecific antibody |
-
2018
- 2018-10-09 MA MA050354A patent/MA50354A/fr unknown
- 2018-10-09 SG SG11202003111SA patent/SG11202003111SA/en unknown
- 2018-10-09 WO PCT/EP2018/077514 patent/WO2019072870A1/en not_active Ceased
- 2018-10-09 CA CA3075337A patent/CA3075337A1/en active Pending
- 2018-10-09 CN CN201880065319.9A patent/CN111183159B/zh active Active
- 2018-10-09 AU AU2018348431A patent/AU2018348431B2/en active Active
- 2018-10-09 KR KR1020207009687A patent/KR20200063153A/ko active Pending
- 2018-10-09 JP JP2020520050A patent/JP7438939B2/ja active Active
- 2018-10-09 US US16/754,097 patent/US11578133B2/en active Active
- 2018-10-09 EP EP18785593.7A patent/EP3694880A1/en active Pending
-
2020
- 2020-04-06 IL IL273841A patent/IL273841B1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020537520A5 (OSRAM) | ||
| JP2021501744A5 (OSRAM) | ||
| JP2025111463A5 (OSRAM) | ||
| JP2022079549A5 (OSRAM) | ||
| WO2021244089A1 (zh) | 新型冠状病毒（sars-cov-2）刺突蛋白结合分子及其应用 | |
| JP2022177090A5 (OSRAM) | ||
| JP2019107018A5 (OSRAM) | ||
| JP2020534830A5 (OSRAM) | ||
| CA2699834A1 (en) | Improved anti-il-6 receptor antibody | |
| JP2013519364A5 (OSRAM) | ||
| JP2017519501A5 (OSRAM) | ||
| JP2017505125A5 (OSRAM) | ||
| JP2018502050A5 (OSRAM) | ||
| JP2013121353A5 (OSRAM) | ||
| JP2011502137A5 (OSRAM) | ||
| JP2010502183A5 (OSRAM) | ||
| JP2013056885A5 (OSRAM) | ||
| SI2753646T1 (en) | Anti-CD40 antibodies, uses and methods | |
| JP2013543384A5 (OSRAM) | ||
| CN115397852B (zh) | 工程化抗il-2抗体 | |
| JP2017526339A5 (OSRAM) | ||
| JP2015535828A5 (OSRAM) | ||
| FI2155783T4 (fi) | Lajien välisesti spesifinen cd3-epsilon-sitoutumisdomeeni | |
| JP2023093753A5 (OSRAM) | ||
| JP2019521647A5 (OSRAM) |